Livforsakringsbolaget Skandia Omsesidigt Buys New Position in Globe Life Inc. $GL

Livforsakringsbolaget Skandia Omsesidigt bought a new stake in Globe Life Inc. (NYSE:GL) in the 2nd quarter, according to its most recent disclosure with the SEC. The fund bought 47,800 shares of the company’s stock, valued at approximately $8,541,000. Livforsakringsbolaget Skandia Omsesidigt owned approximately 0.06% of Globe Life at the end of the most recent reporting period.

Other hedge funds have also made changes to their positions in the company. CYBER HORNET ETFs LLC acquired a new position in shares of Globe Life in the second quarter valued at approximately $28,000. Hilton Head Capital Partners LLC acquired a new position in shares of Globe Life in the fourth quarter worth $30,000. MUFG Securities EMEA plc purchased a new stake in shares of Globe Life during the second quarter worth $31,000. Torren Management LLC acquired a new stake in shares of Globe Life in the fourth quarter valued at $37,000. Finally, Johnson Financial Group Inc. acquired a new stake in shares of Globe Life in the second quarter valued at $39,000. Institutional investors and hedge funds own 81.61% of the company’s stock.

Globe Life Price Performance

Shares of NYSE:GL opened at $173.41 on Friday. Globe Life Inc. has a 12 month low of $127.85 and a 12 month high of $191.55. The firm has a market capitalization of $13.33 billion, a P/E ratio of 11.51 and a beta of 0.48. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.07 and a quick ratio of 0.07. The company’s fifty day moving average price is $178.77 and its 200 day moving average price is $159.53.

Globe Life (NYSE:GL) last released its quarterly earnings data on Wednesday, July 22nd. The company reported $3.61 earnings per share (EPS) for the quarter, missing the consensus estimate of $3.67 by ($0.06). Globe Life had a net margin of 19.58% and a return on equity of 20.52%. The company had revenue of $1.60 billion during the quarter, compared to analyst estimates of $1.59 billion. During the same quarter in the prior year, the company earned $3.05 EPS. The business’s revenue was up 8.0% on a year-over-year basis. Globe Life has set its FY 2026 guidance at 15.550-15.950 EPS. As a group, sell-side analysts predict that Globe Life Inc. will post 15.71 earnings per share for the current fiscal year.

Globe Life announced that its Board of Directors has authorized a stock buyback plan on Monday, August 10th that permits the company to repurchase $2.50 billion in outstanding shares. This repurchase authorization permits the company to buy up to 17.7% of its shares through open market purchases. Shares repurchase plans are typically an indication that the company’s leadership believes its shares are undervalued.

Globe Life Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Monday, October 5th will be paid a dividend of $0.33 per share. This represents a $1.32 dividend on an annualized basis and a yield of 0.8%. The ex-dividend date is Monday, October 5th. Globe Life’s dividend payout ratio (DPR) is currently 8.76%.

Insider Activity

In other Globe Life news, Director Cheryl Alston sold 8,258 shares of the firm’s stock in a transaction on Thursday, June 25th. The shares were sold at an average price of $179.24, for a total transaction of $1,480,163.92. Following the transaction, the director directly owned 16,621 shares of the company’s stock, valued at approximately $2,979,148.04. This trade represents a 33.19% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Thomas Peter Kalmbach sold 25,650 shares of Globe Life stock in a transaction on Tuesday, July 28th. The shares were sold at an average price of $178.58, for a total transaction of $4,580,577.00. Following the completion of the transaction, the chief financial officer owned 50,568 shares in the company, valued at approximately $9,030,433.44. This represents a 33.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 151,908 shares of company stock worth $27,239,981 over the last ninety days. 2.11% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

GL has been the topic of several recent research reports. Morgan Stanley upped their price target on Globe Life from $181.00 to $208.00 and gave the stock an “overweight” rating in a report on Monday, July 6th. Weiss Ratings cut shares of Globe Life from a “buy (b)” rating to a “buy (b-)” rating in a report on Monday, July 20th. Jefferies Financial Group raised their price objective on shares of Globe Life from $147.00 to $166.00 and gave the company a “hold” rating in a report on Friday, July 10th. JPMorgan Chase & Co. lifted their price objective on shares of Globe Life from $181.00 to $201.00 and gave the stock an “overweight” rating in a research report on Tuesday, July 21st. Finally, Keefe, Bruyette & Woods lowered their target price on shares of Globe Life from $192.00 to $190.00 and set an “outperform” rating for the company in a research note on Friday, July 24th. One equities research analyst has rated the stock with a Strong Buy rating, eight have assigned a Buy rating and two have assigned a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $191.67.

Globe Life Profile

Globe Life, traded on the NYSE under the symbol GL, is a U.S.-based insurance holding company that underwrites and distributes a range of life and supplemental health insurance products. Through its subsidiary brands—Globe Life, American Income Life, Liberty National Life, United American Insurance Company and Family Heritage Life—it offers term life, whole life, fixed annuities and supplemental health coverage designed to meet the needs of individuals and families across various socioeconomic segments.

The company’s product suite includes low-cost, easy-to-understand life insurance policies, accidental death and dismemberment coverage, hospital indemnity plans and specified disease insurance.